Signify, a home health company that recently entered into an agreement to be acquired by CVS, is expanding its in-home diagnostic and preventive services by making them available to customers on Medicare Advantage and Medicaid plans.
The latest offering of Signify's diagnostic services adds spirometry testing to detect chronic obstructive pulmonary disease to its previous service line of testing for peripheral arterial disease, colorectal cancer, chronic kidney disease, diabetes and low bone density.
These tests are performed during Signify's home health evaluation, according to an Oct. 18 Signify news release provided to Becker's.
"Early diagnosis and management of chronic conditions are critical to achieving better health outcomes and reducing the total cost of care," Signify Chief Medical Officer Marc Rothman, MD, said. "At Signify, we are performing diagnostic tests in the home to reduce barriers to timely diagnosis and treatment decisions by individuals and their physicians."